FAMOTIDINE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Famotidine, and what generic alternatives are available?
Famotidine is a drug marketed by Ajanta Pharma Ltd, Akorn, Alkem Labs Ltd, Amneals Pharms, Annora Pharma, Carnegie, Cerovene Inc, Lupin Ltd, Micro Labs, Navinta Llc, Novel Labs Inc, Novitium Pharma, Upsher Smith Labs, Apotex Inc, Apothecon, Fresenius Kabi Usa, Hikma, Hospira, Mylan Labs Ltd, Sagent, Zydus Pharms, Perrigo, Actavis Elizabeth, Alembic Pharms Ltd, Apotex, Ascent Pharms Inc, Aurobindo Pharma, Aurobindo Pharma Ltd, Carlsbad, Chartwell Rx, Contract Pharmacal, Dr Reddys Labs Ltd, Glenmark Pharms Inc, Graviti Pharms, Ivax Sub Teva Pharms, Mankind Pharma, Marksans Pharma, Mylan, Mylan Pharms Inc, P And L, Perrigo R And D, Rising, Sandoz, Sun Pharm Inds Ltd, Sun Pharm Industries, Teva, Vkt Pharma, Watson Labs, Epic Pharma Llc, Abbvie, and Baxter Hlthcare. and is included in eighty-one NDAs.
The generic ingredient in FAMOTIDINE is calcium carbonate; famotidine; magnesium hydroxide. There are two hundred and eighty-two drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the calcium carbonate; famotidine; magnesium hydroxide profile page.
Summary for FAMOTIDINE
US Patents: | 0 |
Applicants: | 51 |
NDAs: | 81 |
Finished Product Suppliers / Packagers: | 131 |
Raw Ingredient (Bulk) Api Vendors: | 83 |
Clinical Trials: | 112 |
Patent Applications: | 6,889 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for FAMOTIDINE |
Drug Sales Revenues: | Drug sales revenues for FAMOTIDINE |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for FAMOTIDINE |
What excipients (inactive ingredients) are in FAMOTIDINE? | FAMOTIDINE excipients list |
DailyMed Link: | FAMOTIDINE at DailyMed |
Recent Clinical Trials for FAMOTIDINE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Mainline Biosciences, Inc. | Early Phase 1 |
Assistance Publique - Hôpitaux de Paris | Phase 2/Phase 3 |
INSERM U 1163 - Laboratory of molecular mechanisms of hematologic disorders and therapeutic implications, Paris | Phase 2/Phase 3 |
Pharmacology for FAMOTIDINE
Drug Class | Histamine-2 Receptor Antagonist |
Mechanism of Action | Histamine H2 Receptor Antagonists |